ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab
{{output}}
Background: While amyloid-β (Aβ) biomarker positivity is sufficient before initiating anti-Aβ antibody therapy, recent revised criteria also highlight the importance of other biomarkers (ATNIVS) to understand heterogeneity in ... ...
